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Background: Mendelian randomization studies in adults suggest that abdominal adiposity is causally 115 
associated with increased risk of type 2 diabetes and coronary heart disease in adults, but its causal 116 
effect on cardiometabolic risk in children remains unclear. 117 
Objective: To study the causal relationship of abdominal adiposity with cardiometabolic risk factors 118 
in children by applying Mendelian randomization. 119 
Design: We constructed a genetic risk score using variants previously associated with waist-hip ratio 120 
adjusted for BMI (WHRadjBMI) and examined its associations with cardiometabolic factors by linear 121 
regression and Mendelian Randomization in a meta-analysis of six cohorts, including 9,895 European 122 
children and adolescents aged 3-17 years. 123 
Results: WHRadjBMI genetic risk score was associated with higher WHRadjBMI (beta=0.021 SD/allele, 124 
CI95% 0.016, 0.026, P=3×10-15) and with unfavorable concentrations of blood lipids (higher LDL 125 
cholesterol: beta=0.006 SD/allele, 95% 0.001, 0.011, P=0.025; lower HDL cholesterol: beta=-0.007 126 
SD/allele, CI95% -0.012, -0.002, P=0.009; higher triglycerides: beta=0.007 SD/allele, CI95% 0.002, 127 
0.012, P=0.006). No differences were detected between pre-pubertal and pubertal/post-pubertal 128 
children. The WHRadjBMI genetic risk score had a stronger association with fasting insulin in children 129 
and adolescents with overweight/obesity (beta=0.016 SD/allele, CI95% 0.001, 0.032, P=0.037) than 130 
in those with normal weight (beta=-0.002 SD/allele, CI95% -0.010, 0.006, P=0.605) (P for 131 
difference=0.034). In a two-stage least-squares regression analysis, each genetically instrumented one 132 
SD increase in WHRadjBMI increased circulating triglycerides by 0.17 mmol/l (0.35 SD, P=0.040), 133 
suggesting that the relationship between abdominal adiposity and circulating triglycerides may be 134 
causal. 135 
Conclusions: Abdominal adiposity may have a causal, unfavorable effect on plasma triglycerides 136 
and potentially other cardiometabolic risk factors starting in childhood. The results highlight the 137 
importance of early weight management through healthy dietary habits and physically active 138 
lifestyle among children with tendency for abdominal adiposity. 139 
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Introduction 140 
Childhood obesity has increased worldwide during the last four decades (1) and is associated with 141 
cardiometabolic impairments, including insulin resistance, dyslipidemia, and hypertension in young 142 
age (2). Obesity during childhood often tracks into adulthood where it is associated with an increased 143 
risk and earlier onset of type 2 diabetes and cardiovascular disease (3). It is crucial to fully understand 144 
the factors that contribute to increased cardiometabolic risk starting in childhood, in order to develop 145 
early interventions and treatment strategies to risk groups. 146 
 Observational studies in adults suggest that obesity is a heterogeneous condition and 147 
that for any given amount of body fat, its regional distribution, particularly when located within the 148 
abdominal cavity, is an independent risk factor of cardiometabolic disease (4).  In this regard, waist 149 
circumference has been shown to add to BMI in risk assessment. A study implementing a Mendelian 150 
randomization approach suggested that the link between abdominal adiposity and cardiometabolic 151 
risk may be causal (5). Mendelian randomization utilizes the random assortment of genetic variants 152 
at conception to reduce and limit confounding and reverse causality (6). When using a genetic risk 153 
score (GRS) comprising 48 known variants for waist-hip ratio (WHR) adjusted for BMI (WHRadjBMI) 154 
(7), a genetically instrumented increase in WHRadjBMI was associated with higher levels of 155 
triglycerides, 2-hour glucose, and systolic blood pressure, as well as an increased risk of type 2 156 
diabetes and coronary heart disease, suggesting that the relationship between abdominal adiposity 157 
and cardiometabolic risk may be causal in adults (5). Similar to adults, increased WHR indicates 158 
abdominal adiposity in childhood (8), and gene variants increasing WHRadjBMI have been associated 159 
with a higher ratio of visceral to subcutaneous fat in children and adolescents (9). However, it remains 160 
unclear whether abdominal adiposity is causally linked to increased levels of blood lipids, insulin 161 
resistance, and blood pressure among children and adolescents (10-13). 162 
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In the present study, we aimed to examine the causal relationships of abdominal 163 
adiposity with cardiometabolic risk factors by applying Mendelian randomization in a meta-analysis 164 
of 9,895 children and adolescents from the United Kingdom, Finland, and Denmark.  165 
 166 
Methods 167 
Study populations 168 
The present study includes i) 5,474 children 8-11 years of age from the Avon Longitudinal Study of 169 
Parents and Children (ALSPAC) (14, 15); ii) 2,099 Finnish children and adolescents 3-18 years of 170 
age from the Cardiovascular risk in Young Finns Study (YFS) (16); iii) 705 Danish children and 171 
adolescents 3-18 years of age with overweight or obesity as well as a population-based control sample 172 
consisting of 361 Danish children and adolescents 6-17 years of age from The Danish Childhood 173 
Obesity Biobank (17); hereafter named TDCOB cases and controls, respectively; iv) 470 Finnish 174 
adolescents 14-15 years of age from the Special Turku Coronary Risk Factor Intervention Project 175 
(STRIP) (18); v) 460 Finnish children 6-9 years of age from the Physical Activity and Nutrition in 176 
Children (PANIC) study (19) and vi) 326 Danish children 3 years of age from the Småbørns Kost Og 177 
Trivsel (SKOT) I and II studies (20). (Supplemental Figure 1). Details on the recruitment, inclusion 178 
criteria and ethical approvals of the participating studies are presented in Supplemental Methods. 179 
Children with a history of type 1 or type 2 diabetes, mental or developmental disorders, 180 
or monogenic obesity; children with medication for hypercholesterolemia or hypertension; children 181 
of non-European genetic ancestry based on genome-wide principal component analysis (YFS, 182 
TDCOB, STRIP and SKOT) or self-reported ethnicity (ALSPAC, PANIC), were excluded. For twin-183 
pairs, one twin was excluded. The categories of self-reported ethnicity in the ALSPAC cohort were 184 
“black”, “yellow”, and “white”. The categories of self-reported ethnicity in the PANIC cohort were 185 
“Caucasian” and “non-Caucasian”. We excluded all ALSPAC participants whose self-reported 186 
ethnicity was “black” or “yellow”, and PANIC participants whose self-reported ethnicity was “non-187 
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Caucasian”, due to these ethnicities being considered to represent non-European genetic ancestry for 188 
whom the genetic architecture (allele frequencies, effect sizes) differ from European genetic ancestry. 189 
The analytic codes for the exclusion of participants in the ALSPAC and PANIC cohorts based on 190 
self-reported ethnicity are provided in the Supplemental Methods.  191 
 192 
Measurements of body size and composition, cardiometabolic risk factors, and pubertal status  193 
Body height and body weight were measured in all studies, and BMI was calculated as body weight 194 
(kg) divided by height squared (m2). BMI-SDS was calculated according to UK (ALSPAC) (21), 195 
Finnish (PANIC, STRIP and YFS) (22) and Danish (SKOT, TDCOB cases and TDCOB controls) 196 
(23) national reference values. Waist circumference was measured at mid-distance between the 197 
bottom of the rib cage and the top of the iliac crest. Hip circumference was measured at the level of 198 
the greater trochanters. Body fat mass, body lean mass, and body fat percentage were measured using 199 
bioimpedance analysis (STRIP, SKOT) or dual-energy X-ray absorptiometry (PANIC, ALSPAC, 200 
TDCOB). Blood pressure was measured manually using calibrated sphygmomanometers (PANIC, 201 
YFS) or an oscillometric device (ALSPAC, TDCOB, STRIP, SKOT). Blood samples were taken after 202 
an overnight fast in ALSPAC, YFS, TDCOB, STRIP and PANIC studies and after >2h fasting in 203 
SKOT.  Plasma glucose was measured using the hexokinase method, and serum insulin was analyzed 204 
by immunoassays. Triglycerides, total, LDL, and HDL cholesterol were measured enzymatically. 205 
Overweight and obesity were defined using the age- and sex-specific BMI cut-offs of the International 206 
Obesity Task Force (IOTF) (24). In YFS, TDCOB cases, STRIP, and PANIC studies, the research 207 
physician or the study nurse assessed pubertal status using the 5-stage criteria described by Tanner 208 
(25, 26).  Boys were defined as having entered clinical puberty if their testicular volume assessed by 209 
an orchidometer was ≥4 ml (Tanner Stage ≥2). Girls were defined as having entered clinical puberty 210 
if their breast development had started (Tanner Stage ≥2). Among TDCOB controls, pubertal staging 211 
was obtained via a questionnaire with picture pattern recognition of the five different Tanner stages 212 
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accompanied by a text describing each category. To divide children and adolescents into pre-puberty-213 
onset and onset/ post-onset groups, children with Tanner Stage 1 were considered pre-onset, and all 214 
others were considered onset/post-onset. Children in the SKOT study (aged 3 years) were all 215 
considered prepubertal. Children 8-11 years of age in the ALSPAC were excluded from analyses 216 
using puberty stratification due to insufficient information on puberty. These assessments have been 217 
previously described in detail for each study population (18, 27-31). 218 
Genotyping, imputation and genetic risk score construction 219 
Children in YFS, TDCOB, and SKOT were genotyped using the Illumina Infinium 220 
HumanCoreExome BeadChip (Illumina, San Diego, CA, USA) (32). Children in STRIP were 221 
genotyped using the Illumina Cardio-MetaboChip (33).  Children in PANIC were genotyped using 222 
the Illumina HumanCoreExome Beadchip and the Illumina Cardio-MetaboChip, and the genotypes 223 
from the two arrays were combined. Children in ALSPAC were genotyped using the Illumina 224 
HumanHap550 Quad chip. In all studies, genotype imputation was performed using the 1000 225 
Genomes reference panel (34).  226 
To construct the WHRadjBMI GRS, we used 49 single nucleotide polymorphisms (SNPs) known 227 
to associate with WHRadjBMI in the largest available genome-wide association study (GWAS) 228 
published at the time of the present analyses, including up to 224,459 adults from the Genetic 229 
Investigation of Anthropometric Traits (GIANT) consortium (7)  (Supplemental Table 1). One of 230 
the SNPs, rs7759742, was not available in all six studies of the present meta-analysis and was 231 
therefore excluded from the final GRS. The established WHRadjBMI variants were extracted either as 232 
alleles from the genotyped datasets or dosages from the imputed datasets of each cohort. The GRS 233 
was then calculated as the sum of the number of WHRadjBMI - increasing number of alleles or dosages: 234 
WHRadjBMI genetic risk score = SNP1 + SNP2 + SNP3 + …. SNPn; where SNP is the number of alleles 235 
or dosage of the WHRadjBMI-raising allele (i.e. ranging from 0-2 WHRadjBMI-raising alleles per locus). 236 
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Statistical methods 237 
All statistical analyses and construction of GRS were performed using R software, version 3.3.1. 238 
Linear regression models for inverse normally transformed residuals, adjusted for age, sex, puberty 239 
(YFS, TDCOB, STRIP, PANIC), and study group, if needed (SKOT, STRIP), and first three genome-240 
wide principal components were used to examine the associations of WHRadjBMI GRS with 241 
cardiometabolic risk factors. For WHR, we additionally adjusted the residuals for BMI. For systolic 242 
and diastolic blood pressure, we additionally adjusted the residuals for height. Variables were rank 243 
inverse normally transformed to approximate normal distribution with a mean of 0 and a standard 244 
deviation (SD) of 1. Thus, the effect sizes are reported in SD units of the inverse normally transformed 245 
traits. We also studied the associations of WHRadjBMI GRS with cardiometabolic risk factors stratified 246 
by puberty (pre-onset vs. onset/post-onset). The results from the different studies were pooled by 247 
fixed effect meta-analyses using the ‘meta’ package of the R software, version 4.6.0 (35). Independent 248 
samples t-test was used to compare differences in the effects of the GRS for cardiometabolic risk 249 
factors between groups. The associations of the WHRadjBMI GRS with potential confounding lifestyle 250 
factors were examined by linear regression adjusted for age and sex in ALSPAC. We estimated the 251 
causal effects of WHRadjBMI on cardiometabolic risk factors using two-staged least-squares regression 252 
analyses, implemented in the ’AER’ R-package (v1.2-6) including all studies from which information 253 
on WHR was available (ALSPAC, TDCOB, STRIP, PANIC). We tested for differences between the 254 
estimates from linear regression and instrumental variable analyses using the Durbin-Wu-Hausman 255 
test and assessed the strength of the genetic instrument by calculating the F-statistic (36). We tested 256 
for potential directional pleiotropy in the genetic instrument using the intercept from Egger regression 257 
implemented in the ‘MendelianRandomization’ R-package (v0.3.0). Hereby, deviation of the Egger 258 
intercept from zero provides evidence for pleiotropy (37). Using the same package we performed 259 
additional sensitivity analyses to confirm that the direction of effect that we observed in least squares 260 
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regression analysis was consistent with effect estimates based on multiple genetic variants derived 261 
from Egger regression and weighted median methods. 262 
 263 
Results 264 
Characteristics  265 
Of the 9,895 children and adolescents, 50% were girls and 22% exhibited overweight or obesity 266 
(Table 1). The mean age was 10.0 years (range 2.7-18.0 years). Altogether, 54% of the children and 267 
adolescents were defined as pre-pubertal after excluding participants of the ALSPAC study due to 268 
lack of information on their pubertal status. 269 
Association of the WHRadjBMI GRS with cardiometabolic risk factors in children and adolescents 270 
A key assumption of the Mendelian randomization approach is that genetic variants used as an 271 
instrument are associated with the exposure variable. In a meta-analysis of all 9,895 children and 272 
adolescents from the six studies, we found that the WHRadjBMI GRS, calculated as the unweighted 273 
sum of the number of WHRadjBMI-raising alleles (7), was robustly associated with higher WHRadjBMI 274 
(beta=0.021 SD/allele, CI95% 0.016, 0.026, P=3×10-15).  275 
The primary outcome variables of the present analyses were circulating LDL 276 
cholesterol, HDL cholesterol and triglycerides, fasting glucose, fasting insulin, systolic blood 277 
pressure, and diastolic blood pressure. We found that the WHRadjBMI-increasing GRS was associated 278 
with unfavorable concentrations of blood lipids (higher LDL cholesterol: beta=0.006 SD/allele, CI 279 
95% 0.001, 0.011, P=0.025; lower HDL cholesterol: beta=-0.007 SD/allele, CI95% -0.012, -0.002, 280 
P=0.009; higher triglycerides: beta=0.007 SD/allele, CI95% 0.002, 0.012, P=0.006). There were no 281 
associations between the WHRadjBMI GRS and fasting glucose, fasting insulin, systolic blood pressure 282 
or diastolic blood pressure (P>0.05) (Figure 1, Supplemental Table 2, Supplemental Figure 2). 283 
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In the original GWAS for WHRadjBMI in adults, 20 of the 49 WHRadjBMI loci showed 284 
sexual dimorphism, 19 of which displayed a stronger effect in women (7). In sex-stratified analyses, 285 
we found that the WHRadjBMI GRS had a comparable effect on WHRadjBMI in boys and girls but the 286 
effect on waist circumference was found only in girls (beta=0.013 SD/allele, CI95% 0.005, 0.020, 287 
P=0.001) and not in boys (beta=-0.002 SD/allele, CI 95% -0.009, 0.005, P=0.599) (P for 288 
difference=0.006). The WHRadjBMI GRS was also associated with decreased BMI-SDS in boys 289 
(beta=-0.008 SD/allele, CI95% -0.015, -0.002, P=0.016) but had no effect on BMI-SDS in girls 290 
(beta=0.002 SD/allele, CI95% -0.004, 0.009, P=0.450) (P for difference=0.022). Finally, we also 291 
found a difference between sexes (P for difference=3×10-4) in the effect of the WHRadjBMI GRS on 292 
diastolic blood pressure; the WHRadjBMI GRS had a blood pressure-increasing effect in girls 293 
(beta=0.0109 SD/allele, CI95% 0.005, 0.017, P=0.001) but not in boys (beta=-0.006, 95% CI -0.013, 294 
0.001, P=0.072). No differences were found in other cardiometabolic risk factors between girls and 295 
boys (p>0.05). 296 
A previous mendelian randomization study in adults (5) found a significant inverse 297 
association between the WHRadjBMI GRS and BMI and thus performed sensitivity analyses using a 298 
WHRadjBMI GRS where all variants associated with BMI (P<0.05) were excluded. We only found a 299 
significant inverse association between the WHRadjBMI GRS and BMI in boys, and thus performed 300 
boys-specific sensitivity analyses using a GRS constructed of only those 19 WHRadjBMI SNPs that 301 
have not been associated with BMI in the largest GWAS thus far published in adults (P>0.05) (38). 302 
Comparing the results between the 19 SNP GRS and the full 48 SNP GRS in boys (Supplemental 303 
Table 3), we found very similar effect sizes in the associations of the two scores with cardiometabolic 304 
risk traits, except for the expected differences in BMI and related adiposity measures. The results 305 
were similar when comparing effect sizes between the 19 SNP GRS and the 48 SNP GRS in all 306 
children (Supplemental Table 4). 307 
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Puberty has a major effect on body fat distribution (39). We performed additional analyses 308 
stratified by puberty status to test whether the relationship between WHRadjBMI GRS and 309 
cardiometabolic risk factors is established before puberty, but no differences were found (P>0.05).  310 
A previous study in the TDCOB cohort suggested that there may be differences in genetic 311 
influences on body fat distribution between children who are overweight/obese and those who are 312 
normal-weight (40). We performed analyses stratified by weight status to test whether the effect of 313 
the WHRadjBMI GRS on body fat distribution and cardiometabolic risk is modified by 314 
overweight/obesity. The WHRadjBMI GRS was associated with fasting insulin in children and 315 
adolescents with overweight/obesity (beta=0.016 SD/allele, CI95% 0.001, 0.032, P=0.037) but not in 316 
those with normal weight (beta=-0.002 SD/allele, CI95% -0.010, 0.006, P=0.564) (P for 317 
difference=0.034). Furthermore, the WHRadjBMI GRS was also associated with HDL cholesterol in 318 
children with overweight and obesity (beta=-0.018 SD/allele, CI95% -0.030, -0.006, P=0.036) but 319 
not in children with normal body weight (beta=-0.004 SD/allele CI95% -0.010, 0.001, P=0.121) (P 320 
for difference=0.036). No differences were found in other cardiometabolic risk factors between 321 
children with overweight/obesity and those with normal body weight (p>0.05). 322 
Instrumental variable analyses 323 
We estimated the causal effects of WHRadjBMI on the three traits that the WHRadjBMI GRS was 324 
significantly associated with (triglycerides, HDL cholesterol, and LDL cholesterol) (Supplemental 325 
Table 2) using two-staged least-squares regression analyses. The observational associations of 326 
WHRadjBMI with cardiometabolic risk factors are shown in Supplemental Table 5. In two-stage least-327 
squares regression analysis, each genetically instrumented one SD increase in WHRadjBMI increased 328 
circulating triglycerides by 0.17 mmol/l (0.35 SD per allele, P=0.040, Figure 2, Supplemental 329 
Figure 3) indicating a causal relationship. No difference was found between the observational results 330 
and genetically instrumented results in the Durbin-Wu Hausman test (PALSPAC>0.05). There was no 331 
evidence of pleiotropy in the genetic instrument using the Egger intercept test (Estimate= -0.001, 332 
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CI95% -0.011, 0.009, Pintercept for triglycerides=0.841). The estimates from Egger regression and 333 
weighted median regression were directionally consistent with those derived from the two-stage least 334 
squares method. The two-stage least-squares regression analyses did not suggest that a genetically 335 
instrumented increase in WHRadjBMI has a causal effect on HDL cholesterol (0.24 SD per allele, 336 
P=0.138) or LDL cholesterol (0.19 SD per allele, P=0.259) (Figure 2).  337 
 To conduct a valid Mendelian randomization analysis, the instrumental variable must 338 
not be associated with possible confounders that could bias the relationship between the exposure and 339 
the outcome, and it must relate to the outcome phenotype only through its association with the 340 
exposure and not through pleiotropy (6). Some lifestyle and environmental factors, for example 341 
physical activity and dietary habits, have been associated with body fat distribution (4) and 342 
cardiometabolic risk, and could therefore confound the association between WHRadjBMI and 343 
cardiometabolic risk factors. However, we did not find an association between the WHRadjBMI GRS 344 
and any of the potential confounders we tested in the ALSPAC cohort, including objectively 345 
measured physical activity (p=0.508) sedentary time (p=0.580), family socioeconomic status 346 
(p=0.676), total energy intake (p=0.744), and dietary intakes (E%) of protein (p=0.661), total fat 347 
(p=0.193), saturated fat (p=0.413), monounsaturated fat (p=0.168), polyunsaturated fat (p=0.306), 348 
carbohydrates (p=0.467), and added sugar (p=0.201). We acknowledge that unobserved confounders 349 
could still be present that we were not able to control for.  350 
 351 
Discussion 352 
In the present study, genetic predisposition to higher WHRadjBMI was associated with higher 353 
triglycerides, lower HDL cholesterol, and higher LDL cholesterol in children and adolescents. The 354 
associations of the WHRadjBMI GRS with lipids were similar between prepubertal and pubertal/post-355 
pubertal children and adolescents, indicating that this relationship is established already before 356 
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puberty. Instrumental variable analyses indicated that higher WHRadjBMI may be causally associated 357 
with higher triglycerides. 358 
Sex and age have major effects on WHRadjBMI (39). Sexual dimorphism in body 359 
composition emerges primarily during pubertal development and is driven by the action of sex 360 
steroids (41). Women typically have overall higher body fat content, whereas men have a more central 361 
body fat distribution. The WHRadjBMI GRS, constructed of the 49 loci, also shows a stronger effect 362 
on WHRadjBMI in women than in men (7). In contrast to adults, we observed that the WHRadjBMI GRS 363 
had a comparable effect on WHRadjBMI in children regardless of sex. However, the effect on waist 364 
circumference was higher in girls than in boys. Previous studies have shown that sexual dimorphism 365 
in body fat distribution is distinct already in the first six years of age, characterized by an average 366 
smaller waist and larger hip circumference in girls (42). However, unlike in adulthood, the difference 367 
in this age is more pronounced for waist circumference than for hip circumference (42), which could 368 
partly explain why the genetic influences on waist circumference seem more pronounced in girls than 369 
in boys during childhood but not in adulthood.  370 
The effects of the WHRadjBMI GRS on fasting insulin and HDL cholesterol were more 371 
pronounced among children and adolescents with overweight/obesity than among those with normal 372 
body weight, indicating that higher overall adiposity may enhance the harmful effect of genetic 373 
predisposition to abdominal adiposity on insulin resistance and dyslipidemia. Although the biological 374 
mechanisms for this enhancement are uncertain, we speculate that higher overall adiposity may lead 375 
to a suppressed capacity of subcutaneous fat tissue to store additional fat and a higher deposition of 376 
fat in visceral and other ectopic storage sites. The metabolically active visceral fat releases a number 377 
of inflammatory cytokines as well as a flux of free fatty acids into portal circulation. This may, in 378 
turn, impair hepatic metabolism, thereby leading to reduced hepatic insulin clearance, increased 379 
production of triglyceride-rich lipoproteins, and increased hepatic glucose production (43, 44). Thus, 380 
increased visceral fat has a central role in the development of insulin resistance. Higher overall 381 
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adiposity also results in greater storage of abdominal subcutaneous fat which has a high lipolytic 382 
activity and increases the flux of free fatty acids, contributing to insulin resistance and cardiovascular 383 
risk (45). This impact may be particularly relevant in children who have a relatively large volume of 384 
abdominal subcutaneous fat compared to visceral fat (12, 13). 385 
Previous studies in adults support the role for gradually increasing visceral fat as a 386 
determinant of unfavorable changes in plasma lipid concentrations with advancing age (46). Although 387 
the effect sizes of the GRS for WHRadjBMI on WHRadjBMI and cardiometabolic risk factors in children 388 
and adolescents in the present study were generally weaker than in adults (7), it remains unclear how 389 
age plays into the observed causal relationships as partly different variants may associate with 390 
WHRadjBMI in different ages.  391 
The strength of the present study is the comprehensive data on anthropometry, 392 
cardiometabolic risk factors, and genetic variation from several European child cohorts. To our 393 
knowledge, this is the first study investigating the causal associations of abdominal adiposity on 394 
cardiometabolic risk factors by Mendelian Randomization in children. Limitations of the study are 395 
the use of adult GWAS-based variants for WHRadjBMI, which may not all be associated with 396 
abdominal adiposity in children. Furthermore, we did not address the possibility of bi-directional 397 
relationships between WHRadjBMI and cardiometabolic risk factors in children. Despite the large 398 
sample size, our study may have been underpowered to detect a difference for the studied outcome 399 
traits. In the present analysis, we did not correct for multiple testing due to many of the outcome traits 400 
being correlated, and we acknowledge that adjustment of the significance threshold could reduce the 401 
statistical power further. Finally, as our study only included children of European genetic ancestry, 402 
the results cannot be generalized to other ethnic groups.  403 
 404 
Conclusions 405 
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Our results suggest that there may be a causal, unfavorable effect of abdominal adiposity on plasma 406 
triglycerides in childhood, providing new insights into the relationship between body fat distribution 407 
and cardiometabolic risk in young age. The results underscore the importance of early weight 408 
management through healthy dietary habits and physically active lifestyle among children with 409 
tendency for abdominal fat accumulation. 410 
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Table 1. Characteristics of children and adolescents in the studies included in the present meta-analyses. 
 
       ALSPAC YFS TDCOB cases TDCOB 
controls 
STRIP PANIC SKOT 
N (total) 5474 2099 705 361 470 460 326 
Girls (%) 2754 (50%) 1139 (54%) 415 (59%) 238 (66%) 227 (48%) 219 (48%) 154 (47%) 
Prepubertal (%)1 NA 1244 (51%) 314 (45%) 73 (22%) 0 (0%) 448 (97%) 326 (100%) 
Overweight/obese2 1088 (20%) 161 (8%) 699 (99%) 46 (13%) 54 (12%) 56 (12%) 34 (10%) 
Age (years) 9.9 (0.32) 9.8 (4.0) 11.5 (2.9) 13.0 (3.1) 15.0 (0.0) 7.6 (0.4) 3.0 (0.1) 
Body height (cm) 139.6 (6.3) 137 (25) 152 (16) 157 (16) 170 (8) 129 (6) 96.2 (3.6) 
Body weight (kg) 34.7 (7.3) 35.1 (16.5) 64.9 (23.9) 48.4 (15.3) 61.3 (6.9) 26.7 (4.8) 14.9 (1.7) 
BMI (kg/cm2) 17.7 (2.8) 17.4 (2.8) 27.0 (5.3) 19.1 (3.2) 20.5 (3.3) 16.1 (2.0) 16.1 (1.2) 
BMI-SDS 0.29 (1.11) -0.29 (1.00) 2.90 (0.66) 0.31 (1.05) -0.08 (0.97) -0.20 (1.1) 0.43 (0.92) 
Waist circumference (cm) 62.9 (7.7) NA 93 (15) 70 (9) 73 (8) 57 (5) 47 (4) 
Waist-hip-ratio 0.85 (0.0) NA 0.97 (0.07) 0.82 (0.1) 0.80 (0.05) 0.85 (0.0) NA 
Total body lean mass (kg) 24.6 (3.2) NA NA NA 45 (9) 21 (2) NA 
Total body fat mass (kg) 8.5 (5.0) NA 28.0 (12.2) NA 12.7 (7.5) 5.6 (3.3) 2.6 (0.8) 
Body fat percentage (%) 23.2 (9.0) NA 43.6 (5.2) NA 20.9 (9.3) 20 (8) 17.4 (4.3) 
Insulin (mU/l) NA 9.2 (5.8) 6.9 (7.2) 4.5 (2.2) 8.3 (3.5) 4.5 (2.5) 3.2 (3.5) 
Glucose (mmol/l) NA NA 5.2 (0.6) 5.4 (1.1) 4.9 (0.3) 4.8 (0.4) 4.8 (0.6) 
LDL cholesterol (mmol/l)  2.3 (0.6) 3.5 (0.8) 2.5 (0.8) 2.2 (0.5) 2.4 (0.7) 2.3 (0.5) 2.5 (0.6) 
HDL cholesterol (mmol/l) 1.4 (0.3) 1.6 (0.3) 1.2 (0.3) 1.5 (0.3) 1.2 (0.2) 1.6 (0.3) 1.2 (0.2) 
Triglycerides (mmol/l) 1.1 (0.6) 0.65 (0.29) 1.1 (0.6) 0.7 (0.3) 0.85 (0.42) 0.60 (0.25) 1.1 (0.6) 
Systolic blood pressure (mmHg) 103 (9) 111 (12) 114 (12) 114 (10) 117 /12) 100 (7) 96 (8) 
Diastolic blood pressure (mmHg) 57 (6) 68 (9) 65 (8) 62 (7) 61 (9) 61 (7) 61 (7) 
GRSWHRadjBMI, 48 SNPs (number 
of WHRadjBMI increasing risk 
alleles) 
46.1 (4.3) 47.8 (4.4) 46.4 (4.3) 46.2 (4.3) 46.6 (4.8) 48.2 (4.2) 46.5 (4.4) 
Values are mean (SD) or n (%). BMI-SDS= body mass index standard deviation score; GRS= genetic rik score, WHRadjBMI= waist hip ratio adjusted BMI 
1 Children with Tanner Stage 1 were considered pre-onset and all others were considered onset/post-onset (25, 26). 
2 Overweight and obesity were defined using the age and sex-specific BMI cut-offs of the International Obesity Task Force (IOTF) (24).
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Figure 1. 
Linear regression analysis to test the association of the WHRadjBMI-increasing genetic score with 
cardiometabolic variables in all children and adolescents (n=9,895). The results are expressed as beta 
values (confidence intervals) of the inverse-normally transformed traits and are aligned according to 
the WHRadjBM-increasing allele of the genetic score. All analyses are adjusted for age, puberty, and 
first three genome-wide principal components. The effects were pooled using fixed effects models 
meta-analyses. *P-values <0.05. [beta in SD/allele = effect on the inverse-normally transformed trait 
per allele increase]. The numerical values for betas, standard errors, P-values, and sample sizes are 
presented in Supplemental Table 2. 
 
 
Figure 2. Mendelian randomization analysis to test the causal effect of childhood abdominal 
adiposity on LDL cholesterol, HDL cholesterol and triglycerides. The figure shows associations of 
the WHRadjBMI genetic risk score with LDL cholesterol, HDL cholesterol, triglycerides and 
observational WHRadjBMI, as well as the associations of the observational WHRadjBMI with LDL 
cholesterol, HDL cholesterol and triglycerides. The results of instrumental analysis are obtained 
from two-staged least-squares regression analyses. Beta values are expressed as units of standard 
deviation (SD) of the inverse-normally transformed traits. [beta in SD/allele = effect on the inverse-
normally transformed trait per allele increase]. P-values <0.05 are shown in bold. 
